Early Discontinuation of Antithrombotic Treatment Following Left Atrial Appendage Closure

Although antithrombotic treatment is recommended after left atrial appendage closure (LAAC), some patients require discontinuation of antithrombotic treatment after LAAC without evidence on the safety of such a strategy. We sought to evaluate outcomes of patients who had early antithrombotic treatme...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of cardiology 2022-05, Vol.171, p.91-98
Main Authors: Mesnier, Jules, Cruz-González, Ignacio, Arzamendi, Dabit, Freixa, Xavier, Nombela-Franco, Luis, Peral, Vicente, Caneiro-Queija, Berenice, Mangieri, Antonio, Trejo-Velasco, Blanca, Asmarats, Lluis, Regueiro, Ander, McInerney, Angela, Mas-Lladó, Caterina, Estevez-Loureiro, Rodrigo, Laricchia, Alessandra, O'Hara, Gilles, Rodés-Cabau, Josep
Format: Article
Language:English
Subjects:
Anticoagulants
Atrial Appendage - surgery
Atrial Fibrillation - complications
Atrial Fibrillation - drug therapy
Bleeding
Clinical outcomes
Clinical trials
Confidence intervals
Consortia
Contraindications
Death
Fibrinolytic Agents - therapeutic use
Hemorrhage - epidemiology
Humans
Ischemia
Ischemic Stroke
Mortality
Patients
Risk
Safety
Stroke
Stroke - epidemiology
Stroke - etiology
Stroke - prevention & control
Thromboembolism
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although antithrombotic treatment is recommended after left atrial appendage closure (LAAC), some patients require discontinuation of antithrombotic treatment after LAAC without evidence on the safety of such a strategy. We sought to evaluate outcomes of patients who had early antithrombotic treatment discontinuation after LAAC. This is a multicenter study including 1,082 patients who underwent successful LAAC. Early discontinuation of antithrombotic treatment was defined as discontinuation of all antiplatelet/anticoagulant treatment within 6 months following the procedure. A propensity-matched analysis was used to compare outcomes of patients with and without early antithrombotic treatment discontinuation. A total of 148 patients (13.7%) had early antithrombotic treatment discontinuation. In the entire population, antithrombotic treatment discontinuation patients exhibited a lower CHA2DS2-VASc score (p
ISSN:0002-9149
1879-1913
DOI:10.1016/j.amjcard.2022.01.055